What is the share price of Sai Life Sciences Ltd (SAILIFE) today?
The share price of SAILIFE as on 4th August 2026 is ₹1346.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sai Life Sciences Ltd (SAILIFE) share?
The past returns of Sai Life Sciences Ltd (SAILIFE) share are- Past 1 week: 6.76%
- Past 1 month: 7.67%
- Past 3 months: 24.68%
- Past 6 months: 51.67%
- Past 1 year: 65.55%
- Past 3 years: N/A%
- Past 5 years: 74.38%
What are the peers or stocks similar to Sai Life Sciences Ltd (SAILIFE)?
The peers or stocks similar to Sai Life Sciences Ltd (SAILIFE) include:What is the market cap of Sai Life Sciences Ltd (SAILIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sai Life Sciences Ltd (SAILIFE) is ₹28307.40 Cr as of 4th August 2026.What is the 52 week high and low of Sai Life Sciences Ltd (SAILIFE) share?
The 52-week high of Sai Life Sciences Ltd (SAILIFE) is ₹1350 and the 52-week low is ₹778.50.What is the PE and PB ratio of Sai Life Sciences Ltd (SAILIFE) stock?
The P/E (price-to-earnings) ratio of Sai Life Sciences Ltd (SAILIFE) is 81.13. The P/B (price-to-book) ratio is 13.30.Which sector does Sai Life Sciences Ltd (SAILIFE) belong to?
Sai Life Sciences Ltd (SAILIFE) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Sai Life Sciences Ltd (SAILIFE) shares?
You can directly buy Sai Life Sciences Ltd (SAILIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sai Life Sciences Ltd
SAILIFE Share Price
NSE₹1,346.901.01% (+13.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SAILIFE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SAILIFE Performance & Key Metrics
SAILIFE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 81.14 | 13.30 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.02 | 0.49% |
100%
Analysts have suggested that investors can buy this stock
from 6 analysts
Price Upside
Earnings Growth
Rev. Growth
SAILIFE Company Profile
Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRO/CDMO) providing tailored services for pharmaceutical and biotechnology industries, from drug discovery to commercial launch.
BIOCON
PE Ratio
180.37
180.37
1Y Return
11.66%
11.66%
Buy Reco %
71.43
71.43
ANTHEM
PE Ratio
78.98
78.98
1Y Return
10.31%
10.31%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
71.62
71.62
1Y Return
135.34%
135.34%
Buy Reco %
88.89
88.89
ONESOURCE
PE Ratio
-242.44
-242.44
1Y Return
18.63%
18.63%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-482.99
-482.99
1Y Return
2.80%
2.80%
Buy Reco %
0.00
0.00
SAILIFE Sentiment Analysis
SAILIFE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SAILIFE Stock Summary · May 2026
Management framed the quarter as a validation of its integrated CRDMO strategy, reporting revenue growth of 29% year‑on‑year and announcing a stepped‑up FY27 capex program of INR 1,100–1,300 crore to support the next phase of expansion. They highlighted broad‑based growth across CRO and CDMO, deeper multi‑service engagements with large pharma clients and a growing late‑stage pipeline, while stressing priorities on capacity buildouts, automation, DMPK/biology scale, ADC and peptide capability development and targeted AI/digital investments to lift productivity. Management struck a confident but measured tone, noting stronger CDMO visibility and several recently commercialized products expected to contribute in FY27, yet acknowledging tensions: customer concentration and supply‑chain cost pressures, short‑term inefficiencies and margin volatility as new plants commission, and limited visibility on exact commercialization timing. Looking ahead, they said capex will be phased to customer demand, leverage will remain healthy, CDMO growth is expected to continue and they anticipate FY27 second‑half strength as new capacity and investments come online.
SAILIFE Stock Growth Drivers
SAILIFE Stock Growth Drivers
7Robust FY26 financial performance and improved profitability
The company delivered materially stronger FY26 results with revenue up 29%, EBITDA up 56% and
Integrated CRDMO platform and deepening large‑pharma relationships
The company’s integrated discovery‑to‑commercial CRDMO model is a structural differentiator that is increasing its relevance
SAILIFE Stock Challenges
SAILIFE Stock Challenges
5Geopolitical-driven input and logistics cost pressure
Ongoing geopolitical tensions, including developments in the Middle East, have increased input costs and disrupted
Capex-driven near-term financial strain and efficiency drag
A sizable expansion program is elevating costs and creating funding and efficiency risks: the firm
SAILIFE Forecast
SAILIFE Forecasts
Price
Revenue
Earnings
SAILIFE Share Price Forecast
SAILIFE Share Price Forecast
2026
Current
₹1,333.40
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,333.40
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SAILIFE Company Revenue Forecast
SAILIFE Company Revenue Forecast
2026
Current
₹2.24
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.24
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SAILIFE Stock EPS (Earnings Per Share) Forecast
SAILIFE Stock EPS (Earnings Per Share) Forecast
2026
Current
₹16.63
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹16.63
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SAILIFE
SAILIFE
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SAILIFE Income Statement
SAILIFE Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 394.92 | 442.55 | 287.84 | 405.52 | 448.89 | 589.11 | 506.32 | 552.80 | 564.84 | 617.95 | ||||||||||
Operating & Other expenses | 287.29 | 314.55 | 253.61 | 293.34 | 320.03 | 421.93 | 375.49 | 391.65 | 376.90 | 425.59 | ||||||||||
EBITDA | 107.63 | 128.00 | 34.23 | 112.18 | 128.86 | 167.18 | 130.83 | 161.15 | 187.94 | 192.36 | ||||||||||
| Depreciation/Amortization | 31.41 | 31.05 | 31.07 | 35.92 | 34.09 | 37.49 | 37.72 | 39.75 | 44.08 | 45.31 | ||||||||||
| PBIT | 76.22 | 96.95 | 3.16 | 76.26 | 94.77 | 129.69 | 93.11 | 121.40 | 143.86 | 147.05 | ||||||||||
| Interest & Other Items | 23.28 | 20.89 | 21.22 | 20.93 | 23.13 | 10.89 | 12.36 | 9.35 | 9.70 | 7.83 | ||||||||||
| PBT | 52.94 | 76.06 | -18.06 | 55.33 | 71.64 | 118.80 | 80.75 | 112.05 | 134.16 | 139.22 | ||||||||||
| Taxes & Other Items | 13.33 | 19.92 | -4.57 | 13.82 | 17.80 | 30.53 | 20.30 | 28.20 | 33.80 | 34.99 | ||||||||||
| Net Income | 39.61 | 56.14 | -13.49 | 41.51 | 53.84 | 88.27 | 60.45 | 83.85 | 100.36 | 104.23 | ||||||||||
| EPS | 2.19 | 31.00 | -0.74 | 2.22 | 2.89 | 4.24 | 2.90 | 4.01 | 4.77 | 4.93 |
SAILIFE Company Updates
FY 2026FY 2026
Investor Presentation
May 15PDF
Feb 6PDF
Nov 7PDF
Aug 8PDF
SAILIFE Stock Peers
SAILIFE Past Performance & Peer Comparison
SAILIFE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sai Life Sciences Ltd | 81.13 | 13.30 | — |
| Biocon Ltd | 180.37 | 1.90 | 0.12% |
| Anthem Biosciences Ltd | 78.98 | 15.36 | 0.24% |
| Acutaas Chemicals Ltd | 71.62 | 19.33 | 0.16% |
SAILIFE Stock Price Comparison
Compare SAILIFE with any stock or ETFCompare SAILIFE with any stock or ETF
SAILIFE
SAILIFE Holdings
SAILIFE Shareholdings
SAILIFE Promoter Holdings Trend
SAILIFE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SAILIFE Institutional Holdings Trend
SAILIFE Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.52%
SAILIFE Shareholding Pattern
SAILIFE Shareholding Pattern
SAILIFE Shareholding History
SAILIFE Shareholding History
Foreign Institutions
Mutual Funds Invested in SAILIFE
Mutual Funds Invested in SAILIFE
No mutual funds holding trends are available
Top 5 Mutual Funds holding Sai Life Sciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.7567% | Percentage of the fund’s portfolio invested in the stock 1.03% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 205/267 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.0568% | Percentage of the fund’s portfolio invested in the stock 4.90% | Change in the portfolio weight of the stock over the last 3 months -0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 1/72 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.8939% | Percentage of the fund’s portfolio invested in the stock 4.74% | Change in the portfolio weight of the stock over the last 3 months -0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/49 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SAILIFE stock
smallcases containing SAILIFE stock
Looks like this stock is not in any smallcase yet.
SAILIFE Events
SAILIFE Events
SAILIFE Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SAILIFE Dividend Trend
No dividend trend available
SAILIFE Dividends
SAILIFE Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSAILIFE Stock News & Opinions
SAILIFE Stock News & Opinions
Articles & Videos
Corporate
Corporate
Sai Life Sciences to table resultsSai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 August 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allots 92,000 equity shares under ESOPSai Life Sciences has allotted 92,000 equity shares under ESOP on 14 May 2026. With this allotment, the paid up equity share capital has increased to 21,21,15,515 equity shares of Re 1 each.
2 months agoCapital Market - Live
Earnings
Earnings
Sai Life Sciences consolidated net profit rises 18.09% in the March 2026 quarterNet profit of Sai Life Sciences rose 18.09% to Rs 104.24 crore in the quarter ended March 2026 as against Rs 88.27 crore during the previous quarter ended March 2025. Sales rose 3.91% to Rs 602.14 crore in the quarter ended March 2026 as against Rs 579.51 crore during the previous quarter ended March 2025. For the full year,net profit rose 105.08% to Rs 348.91 crore in the year ended March 2026 as against Rs 170.13 crore during the previous year ended March 2025. Sales rose 29.38% to Rs 2192.49 crore in the year ended March 2026 as against Rs 1694.57 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales602.14579.51 4 2192.491694.57 29 OPM %29.3227.19 -28.7923.94 - PBDT184.25156.29 18 641.05366.28 75 PBT138.94118.80 17 474.19227.70 108 NP104.2488.27 18 348.91170.13 105 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences schedules board meetingSai Life Sciences will hold a meeting of the Board of Directors of the Company on 14 May 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allots 11,100 equity shares under ESOPSai Life Sciences has allotted 11,100 equity shares under ESOP on 24 March 2026. With this allotment, the paid up equity share capital has increased to 21,17,79,234 equity shares of Re 1 each. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allots 1.29 lakh equity shares under ESOPSai Life Sciences has allotted 129,007 equity shares under ESOP on 22 February 2026. With this allotment, the paid up equity share capital has increased to 21,17,58,134 equity shares of Re 1 each. Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Spotlight
Sai Life Sciences jumps on strong Q3 showOn a consolidated basis, the company reported revenue from operations of Rs 556 crore in Q3 FY26, up 27% YoY from Rs 440 crore in Q3 FY25. The company said revenue growth during the quarter was driven by strong momentum in both contract research organisation and contract development and manufacturing organisation segments. Profit after tax stood at Rs 100 crore in Q3 FY26, compared with Rs 54 crore a year ago, translating into an 86% YoY increase. PAT margin improved to 18% from 12% in the corresponding quarter last year. Profit before tax surged 87% YoY to Rs 134 crore in Q3 FY26 from Rs 72 crore in the year-ago quarter. EBITDA increased 54% YoY to Rs 191 crore from Rs 124 crore in Q3 FY25, while EBITDA margin expanded to 34% from 28%. The growth was supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives. Sai Life Sciences said it has invested Rs 405 crore in capital expenditure so far, against a planned capex outlay of Rs 700 crore for FY26, in line with its long-term strategy to strengthen capabilities and expand capacity. During the quarter, it successfully completed eight customer audits across its manufacturing and R&D units, with zero data integrity deviations and no critical observations reported. Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said: Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders. Hyderabad-based Sai Life Sciences is one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Sai Life Sciences consolidated net profit rises 86.41% in the December 2025 quarterNet profit of Sai Life Sciences rose 86.41% to Rs 100.38 crore in the quarter ended December 2025 as against Rs 53.85 crore during the previous quarter ended December 2024. Sales rose 26.53% to Rs 556.46 crore in the quarter ended December 2025 as against Rs 439.78 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales556.46439.78 27 OPM %33.7627.23 - PBDT186.53105.74 76 PBT142.4671.65 99 NP100.3853.85 86 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences to table resultsSai Life Sciences will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allots 8.89 lakh equity shares under ESOPSai Life Sciences has allotted 8,89,133 equity shares under ESOP on 19 December 2025. Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 23.28%, vs industry avg of 18.93%
Over the last 5 years, market share increased from 7.19% to 8.5%
Over the last 5 years, net income has grown at a yearly rate of 41.69%, vs industry avg of 12.52%